The time dependency of the antitumour activity of (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)platinum(II) monohydrate (DWA2114R) was examined in mice inoculated i.p. with 105 mouse L1210 leukaemia cells. The increase in life span was greater in mice treated with 72mgkg'I DWA2114R on the 6th day following tumour inoculation than in mice treated at earlier times. Such superior effects against advanced L1210 were also seen with cis-diammine (1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA) but not seen with the parent compound, cis-diamminedichloroplatinum(II) (CDDP) or other antitumour agents devoid of platinum. After the injection of DWA2114R on day 6, most of the ascites tumour cells accumulated in the S and G2/M phases of the cell cycle and the total cell number markedly decreased from 108 to less than 106. On the other hand, only a temporary G, arrest and a less than 50% reduction of the cell number were induced after a similar treatment on day 3. Interestingly, the superiority of DWA2114R for advanced L1210 was lost in athymic nude mice and mice depleted of T cells by anti-thymocyte antisera. In addition, mice cured of advanced L1210 specifically rejected re-inoculated L1210 cells. These results indicate that the superior antitumour activity against advanced L1210 is unique to DWA2114R among the agents tested (except for CBDCA) and is caused by both an increased drug susceptibility of tumour cells and a drug-induced antitumour effect mediated by T cells of the host mice.
The antitumour activity of cis-diamminedichloroplatinum(II) (CDDP) was first described more than 20 years ago (Rosenberg et al., 1969) . CDDP is one of the most potent antitumour drugs for a variety of human cancers in the clinic (Loehrer & Einhorn, 1984) . However, the severe side effects of CDDP such as nephrotoxicity, nausea and vomiting, myelotoxicity, and ototoxicity are dose limiting factors for constraining clinical use (Stark & Howell, 1978; Prestayko et al., 1979) . A great effort has been made world wide to develop new platinum analogs with improved antitumour activity and reduced toxicity. In our laboratories, a series of platinum complexes carrying asymmetrical alicyclic diamines have been tested (Morikawa et al., 1990) . From these compounds, (-)-(R)-2-aminomethylpyrrolidine (1,1-cyclobutanedicaboxylato)platinum(II) monohydrate (DWA2114R) has been selected as an agent with improved nephrotoxicity and potent antitumour activity .
We have revealed that single i.v. injection (day 1) of DWA2114R showed potent antitumour activity against L1210 implanted s.c. (Endo et al., 1992) . Thereafter, in preliminary experiments using advanced L1210 leukaemia in mice, DWA2114R showed an unexpectedly good therapeutic effect. This result made us very interested in the time dependency of the antitumour effect of DWA2114R, since antitumour agents are generally thought to be less active against tumours in advanced stages of progression. In this study, the time dependency of the antitumour activity of DWA2114R and its mechanisms were examined in mice inoculated with L1210 leukaemia cells. The results show that DWA2114R is more active against L1210 in advanced stages than in early stages. The analysis of the antitumour mechanisms in this model suggested that both the direct tumoricidal activity of the drug and T cell mediated immunity of the host mice play important roles in the superior effect of DWA2114R against advanced L1210.
Materials and methods

Drugs
DWA2114R and CBDCA were synthesised in our laboratories by the method described previously (Morikawa et al., 1990) (Table II) . CBDCA as well as DWA21 14R showed the greatest antitumour activity after the injection on day 6. On the other hand, the survival time of the mice treated with CDDP was longest in early injection (day 2) and decreased slightly in progressive order on days 4, 6, and 8.
The time dependency of antitumour activity was also examined for other types of antitumour agents which are devoid of platinum. Four mg kg-' doxorubicin, 60 or 80 mg kg-5-fluorouracil, 100 mg kg-' cyclophosphamide, 1 or 2 mg kg-' vincristine sulfate or 20 mg kg-etoposide was i.p. injected into tumour-bearing mice in an early stage (day 2 or 3) or late stage (day 6) of tumour progression (Table  III) . These agents were more effective by early injection than late, although the differences were not statistically significant in the case of cyclophosphamide or etoposide. The enhancement of antitumour activity by late injection was shown only in DWA2114R among these agents.
Number of ascites tumour cells after DWA2114R injection In order to determine the effect of DWA2114R on tumour cell proliferation, the number of ascites tumour cells was monitored after inoculation of 105 L1210 cells. As shown in Figure 1 , the number of tumour cells per mouse in the control group increased by 10-fold (106/mouse) on day 3 and by 1000-fold (108/mouse) on day 6. Maximally, about 3 x 108 cells were present on day 7 and maintained this level until the animal's death. In the mice injected with 72 mg kg-' DWA2114R on day 3, the ascites cell number decreased by 50% on day 6 and maintained this level until day 9. However, the number then rapidly increased and reached about 108 cells per mouse on day 13. In contrast, the 108 ascites cells number was drastically decreased by more than 99% after the same treatment with the drug on day 6, and less than 106 cells remained on day 15. These results are consistent with the therapeutic effect of DWA21 14R mentioned above.
Cell cycle analysis
The in vivo effect of DWA21 14R on the cell cycle progression of ascites cells was analysed by using a flow cytometer (Figure 2) . Most of the cells from mice without drug treatment on day 3 were present in the GI phase of the cell cycle.
In contrast, the non-treated ascites cells on day 6 showed a typical cell cycle pattern of exponentially proliferating cells and the ratio of the cells in the S and G2/M phases was much higher than that on day 3. The injection of DWA2114R on day 3 slightly decreased the cells in the S phase but increased the GI peak following 72 h (day 3 to 6). However, the ratio of cells in the S and G2/M phases was markedly increased 240 h (day 13) after the drug injection, consistent with the increase in the cell number as shown in Figure 1 . In contrast, the day 6-injection of DWA2114R drastically decreased the GI peak and most of the cells accumulated in S and G2/M in the following 72 h (day 7-9). These cells in S and G2/M then, almost disappeared and the remaining cells almost At this time, about 2 x 106 tumour cells were present in the peritoneal cavity, as described in Figure 1 . Table IV , the median survival time of the control mice was 9 days, which was almost the same as that of CDF1 mice as described above (Tables I, II and III) . However, no advantage of injection in advanced stage of tumour progression on the antitumour activity of DWA2114R was seen in the nude mice. DWA21 14R showed its highest activity after the injection on day 1 at both doses and the activity decreased in the order: days 3, 6 and 8. A critical role of T cells was also convincingly demonstrated using anti-thymocyte antisera. CDF, mice inoculated with L1210 cells were treated with rabbit anti-thymocyte or anti-asialo GM1 antisera to eliminate T cells (Kataoka et al., 1985) or NK cells (Habu et al., 1981) 4 h before the drug injection. As shown in Figure 3 , pretreatment with antithymocyte antisera reduced the antitumour activity of DWA2114R injected on day 3 (about 30% reduction: not significant) or on day 6 (about 50% reduction: P<0.05). On the other hand, the injection of anti-asialo GMI had no effect on the activity of DWA2114R.
We then examined whether the mice cured of L1210 leukaemia by treatment with DWA2114R could eliminate reinoculated L1210 cells. Six mice survived for 35 days after 50 CDF, mice inoculated with 105 L1210 cells per mouse were injected with 72mgkg-' DWA2114R on day 6. Three of these cured mice were reinoculated with 105 L1210 cells, the remaining 3 mice with 105 P388 leukaemia cells. All the mice reinoculated with L1210 cells survived for more than 60 days, whereas none of them inoculated with P388 cells survived more than 20 days.
Discussion
In this study, the antitumour activity of DWA2114R against L1210 leukaemia was shown to be significantly higher in late than in early stage of the disease. The survival time of the mice injected with 72 mg kg' DWA2114R on day 6 was about 2-times greater than that on day 1 (Table I) . Such time dependency of the antitumour activity is unique to two CDDP analogs, DWA2114R and CBDCA since the parent compound CDDP and other antitumour agents showed higher antitumour activity in the early rather than in the late administration by injection (Tables II and III) . These results suggest that DWA2114R and CBDCA have certain unique properties in their antitumour mechanisms. The kinetics of the proliferation and the cell cycle progression of the ascites cells suggest that the susceptibility of the L1210 cells to DWA2114R is much higher on day 6 than on day 3 (Figures 1 and 2) . The injection of DWA2114R on day 6 induced S and G2/M arrest, whereas the same treatment on day 3 only slightly induced GI arrest. From the results of our experiments using exponential L1210 cells in culture, we previously reported that G2 arrest is critical for the cytotoxicity of DWA2114R, whereas GI arrest was not observed under such conditions . This may explain why most of exponential cells on day 6 are highly susceptible to the cytotoxicity of DWA2114R. On the other (Bruce et al., 1966; Van Putten et al., 1972; Bhuyan et al., 1977) . In addition, the flow cytometrical pattern of the drug-treated cells after the day 6-injection of DWA21 14R showed no increase in cell debris. This means a large proportion of the cells arrested in S and G2/M must be rapidly eliminated from the peritoneal cavity of host mice. This suggests that the superiority of DWA21 14R against advanced L1210 should be a result of certain unique actions mediated by the immune systems of host mice. In this regard, the contribution of T cells to the antitumour activity of DWA2114R was reasoned as follows. The superiority of DWA2114R against advanced L1210 was not observed in athymic nude mice (Table IV) and was lost in mice depleted of T cells by injection of anti-thymocyte antisera (Figure 3) . The reduction in the antitumour activity of DWA2114R by the injection of such antisera was larger in the mice treated on day 6 than in those treated on day 3. Moreover, mice cured of advanced L1210 rejected reinoculated L1210 cells. These results suggest that T cells are essential for the superior effect of DWA2114R against advanced tumour and contribute to the establishment of tumour specific immunity.
Although the experimental systems were different, the immuno-potentiating activity against tumour cells has also been seen with other antitumour agents (Kleinerman & Zwelling, 1982; Mokyr & Dray, 1987) . It has also been reported that antitumour immunity is induced in mice treated with CDDP (Kociba et al., 1970; Sarna & Sodhi, 1978) . In an in vitro system, CDDP has been reported to activate spontaneous cell-mediated cytotoxicity (Kleinerman et al., 1980; Mally et al., 1980) but not to activate T cell mediated cytotoxicity (Mally et al., 1979) . These reports indicate that CDDP may have some ability to augment host antitumour immunity. However, the specificity of these rejection responses to tumour and the uniqueness of CDDP to induce these rejections were not examined. It is fascinating to consider the possibility that DWA2114R has unique ability to take advantage of T cell-mediated antitumour immunity. In this regard, it is suggestive that CBDCA which has the same slow-reacting leaving groups as DWA2114R showed a similar time dependency in its antitumour activity. Such similarity between DWA2114R and CBDCA raises the possibility that slow-reacting leaving groups might cause the differences observed between CDDP and these two compounds. More precise analysis of the role of the immune systems in the host mice using various CDDP analogs would elucidate the critical difference of these compounds.
In conclusion, at least two mechanisms are involved in the superior effect of DWA2114R against advanced L1210 leukaemia. First, an increased drug-sensitivity of the tumour cells. Second, T cell-mediated antitumour immunity in the host mice. As discussed above, the latter is thought to be critical for the unique effect of DWA2114R in this model. This experimental system should be useful to elucidate the role of immunological function in the therapeutic effect of the antitumour platinum complexes.
